Volume : 12, Issue : 04, April – 2025
Title:
COMPARATIVE ANALYSIS OF INTRAVENOUS CEFTRIAXONE AND CIPROFLOXACIN FOR THE TREATMENT OF BACTERIAL PERITONITIS IN LIVER CIRRHOSIS: A SINGLE CENTRE STUDY AT GUJRANWALA MEDICAL COLLEGE
Authors :
Muhammad Ali Raza, Abdul Moeed Baig, Muhammad Ehtisham Ul Haq,Dr Sara Saleem
Abstract :
Background:
Spontaneous bacterial peritonitis (SBP) is a life-threatening complication in liver cirrhosis. Early empirical antibiotics improve survival significantly. This study compares intravenous ceftriaxone and ciprofloxacin for treating bacterial peritonitis among cirrhotic patients.
Methods: This prospective study was conducted at Gujranwala Medical College from January to December 2024. Patients with SBP were randomized to receive either intravenous ceftriaxone (2g/day) or ciprofloxacin (400mg twice daily). Clinical response, infection resolution, mortality, and adverse events were recorded.
Results:120 patients were enrolled (60 per group). Clinical resolution at day 5 occurred in 83.3% of the ceftriaxone group versus 71.7% of the ciprofloxacin group (p=0.04). Mortality was lower in the ceftriaxone group (10% vs 18.3%, p=0.18). Both antibiotics were well tolerated.Conclusion:Ceftriaxone showed superior clinical resolution compared to ciprofloxacin in SBP management. It remains preferable as empirical therapy in cirrhotic patients with peritonitis.
Keywords: Liver Cirrhosis, Spontaneous Bacterial Peritonitis, Ceftriaxone, Ciprofloxacin, Cirrhosis Infection
Cite This Article:
Please cite this article in press Muhammad Ali Raza et al., Comparative Analysis Of Intravenous Ceftriaxone And Ciprofloxacin For The Treatment Of Bacterial Peritonitis In Liver Cirrhosis: A Single Centre Study At Gujranwala Medical College, Indo Am. J. P. Sci, 2025; 12(04).
Number of Downloads : 10
References:
1. Runyon BA. Management of adult patients with ascites due to cirrhosis: Update 2012. Hepatology. 2013;57(4):1651-1653.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on ascites, SBP and hepatorenal syndrome. J Hepatol. 2010;53(3):397-417.
3. Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis—in- hospital mortality, predictors of survival. Dig Dis Sci. 2001;46(12):2662-2668.
4. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197-209.
5. Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl 1):S1-S12.
6. Sort P, Navasa M, Arroyo V, et al. Effects of albumin in SBP: NEJM. 1999;341(6):403-409.
7. Rimola A, et al. Diagnosis and management of SBP: J Hepatol. 2000;32(1):142- 153.
8. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology. 1988;8(1):171-175.
9. Piano S, Fasolato S, et al. SBP caused by multidrug-resistant bacteria. Hepatology. 2016;63(3):1035-1042.
10. Hanouneh MA, Hanouneh IA, Hashash JG, et al. Empirical antibiotic therapy in cirrhotic patients. World J Gastroenterol. 2014;20(39):14476-14483.
11. Tandon P, Garcia-Tsao G. Bacterial infections, prophylaxis, and antibiotic resistance in cirrhosis. J Hepatol. 2011;55(4):849-859.
12. Llovet JM, et al. Clinical features of SBP and its diagnosis. J Hepatol. 1997;26(4):743-753.
13. Gustot T, et al. Spontaneous bacterial peritonitis: recent advances. Gut. 2009;58(12):1479-1489.
14. Kim JJ, Tsukamoto MM, Mathur AK, et al. SBP trends and changing microbial resistance. Clin Gastroenterol Hepatol. 2012;10(7):717-723.
15. Fernández J, Navasa M, Planas R, et al. Antibiotic strategies in SBP: Gastroenterology. 2007;133(3):818-824.